Perbedaan Efektivitas antara Cilostazol dan Aspirin terhadap Peningkatan Suhu Sela Jari: Tinjauan terhadap Kaki Diabetik Wagner Derajat II dan III

Muhammad Akbar 'Anifa, Zairin Noor, Nelly Al Audhah

Abstract


ABSTRACT: Diabetes mellitus is a multisystem disease characterized by hyperglycemia due to abnormalities in insulin secretion, insulin mechanism, or both. Hyperglycemia in diabetes will lead to long-term complications, such as, several organs failure or disfunction, especially the eyes, kidneys, nerves, heart and blood vessels. One of the diabetic complications is diabetic foot. The appearance of diabetic foot mainly occurs due to repetitive trauma to the foot. After the appearance of ulcers, diabetic foot was compounded with decreased vascular in the patients, making it more difficult to recover. The poor vascularization for diabetic foot patients implicates falling temperatures of the toes. Cilostazol and aspirin are antithrombotic medicines that cause inhibition activation and aggregation trombosit, and vasodilatation. This study aimed to examine the effect of cilostazol and aspirin on toes temperature of the feet of diabetic patients. This research is an experimental research by calculating the average temperature of the toes of diabetic foot patients before and after the administration of cilostazol and aspirin . The results showed the average temperature of the subject toes before giving cilostazol and aspirin is 33.340C and 33.970C, and after administration is 33.540C and 34.720C. From this research it can be concluded that there is an increase in the temperature of the toes after administration of cilostazol and aspirin on the toes of diabetic foot patients.

 

Keywords : Aspirin, Cilostazol, Diabetes Mellitus, Diabetic Foot

 

ABSTRAK: Diabetes mellitus merupakan suatu penyakit multisistem dengan ciri hiperglikemia akibat kelainan sekresi insulin, kerja insulin, atau kedua-duanya. Hiperglikemia pada diabetes akan mengakibatkan komplikasi jangka panjang seperti, disfungsi atau kegagalan beberapa organ tubuh, terutama mata, ginjal, saraf, jantung dan pembuluh darah. Salah satu komplikasinya adalah kaki diabetik. Kemunculan kaki diabetik terutama terjadi karena adanya trauma berulang pada kaki. Setelah munculnya ulkus, kaki diabetik diperparah dengan daya vaskuler pasien yang menurun, sehingga sulit untuk sembuh. Buruknya vaskularisasi pasien kaki diabetik berimplikasi pada turunnya suhu sela jari kaki. Cilostazol dan aspirin adalah obat antitrombotik yang menyebabkan terjadinya inhibisi aktivasi dan agregasi trombosit, serta vasodilatasi. Penelitian ini bertujuan untuk melihat pengaruh cilostazol dan aspirin terhadap suhu sela jari kaki pada pasien kaki diabetik. Penelitian ini bersifat eksperimental dengan menghitung rata-rata suhu sela jari kaki pasien kaki diabetik sebelum dan setelah pemberian cilostazol dan aspirin. Hasil penelitian menunjukkan rata-rata suhu sela jari kaki subyek sebelum pemberian cilostazol dan aspirin adalah 33,340C dan 33,970C, dan setelah pemberian adalah 33,540C dan 34,720C. Dari hasil penelitian dapat disimpulkan bahwa terdapat peningkatan suhu sela jari kaki setelah pemberian cilostazol dan aspirin pada sela jari kaki pasien kaki diabetik.

 

Kata-kata Kunci : Aspirin, Cilostazol, Diabetes Mellitus, Kaki Diabetik.


Full Text:

PDF

References


Perkeni. Revisi konsensus pengelolaan dan pencegahan diabetes mellitus tipe 2 di Indonesia. Jakarta: Perkeni, 2011.

Hadisaputro S , Setyawan H. Epidemiologi dan faktor-faktor resiko terjadinya diabetes mellitus tipe 2. Dalam: Darmono, dkk, editor. Naskah lengkap diabetes mellitus ditinjau dari berbagai aspek penyakit dalam. Semarang : Badan Penerbit Universitas Diponegoro, 2007: 133-154.

Soegondo S. Penatalaksanaan pasien diabetes mellitus. Jakarta: Penerbit FK UI, 1998.

Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–1053.

Badan Penelitian dan Pengembangan Kesehatan. Hasil riset kesehatan dasar (RISKESDAS) provinsi Kalimantan Selatan 2007. Jakarta: Departemen Kesehatan RI, 2008.

PAPDI. Buku ajar ilmu penyakit dalam edisi kelima. Jakarta: Interna Publishing, 2009.

Howard IM. The prevention of foot ulceration in diabetic patients. Phys Medical Rehabilitation Clinical 2009; 20 (4): 595-609.

Khallaf AN, Fathi O, Ayad W, et al. Diabetic foot ulcers: conservative management as limb salvage. Journal ofPlastReconstruction Surgery 2006; 30 (2): 107-111.

Ahn CW, Lee HC, Park SW, et al. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes ClinicalPractice 2001; 52 (1): 45-53.

Reilly M, Mohler E. Cilostazol: treatmentof intermittent claudication. Pharmacother 2001; 35: 48-56.

Carson SN, Overall K. Adjunctive therapy for ischemic wounds using cilostazol. Journal of Wound Research 2003; 3: 13-17.

Douglas JS, Holmes DR, Kereiakes DJ, et al. Coronary stent restenosis in patient treated with cilostazol. Circulation 2005; 112 (18): 2826-2832.

Ahn JC, Song WH, Kwon JA, et al. Effect of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean Journal of Intern Medical 2004; 19 (4): 230-236.

Okuda Y, Mizutani M, Ikegami T, et al. Hemodynamic effects of cilostazol on peripheral artery in patient with diabetic neuropathy. Arzneimittelforschung 1992; 42 (4): 540-542.

Miyashita Y, Saito S, Miyamoto A, et al. Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology 2001; 62 (1): 15-17.

Dean SM, Vaccaro PS. Successful pharmacologic treatment of lower extremity ulcerations in 5 patients with chronic critical limb ischemia. Journal of Board FamilyPractice 2002; 15 (1): 55-62.

Pradhan L, Andersen ND, Nabzdyk C, et al. Wound-healing abnormalities in Diabetes andnew theraupetic intervention. US Endocrine Disease 2007; 1: 68-72.

Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has benefical effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98 (7): 678-686.

Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl, oxalate, pentoxifylline, and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess 2005; 15 (40): 1-210.

Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia. Farmakologi dan terapi edisi 5. Jakarta: Balai Penerbit FKUI, 2007.

Kelechi TJ, Michel Y. A descriptive study of skin temperature, tissue perfusion, and tissue oxygen in patient with chronic venous disease. Biology Research Nurse 2007; 9 (1): 70-80.

Dominick J.A, Piera C, Shinya G, et al. A randomized study assesing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the Optimus-2 study. European Heart Journal 2008; 29: 2202-2211.

Yining Q, Qi B. Systematic study of cilostazol on secondary stroke prevention : a meta-analysis. Journal of Medical Research 2013; 18 (53): 1-7.

Goto S. Cilostazol: potential mechanism of action for antithrombic effect accompanied by a low rate of bleeding. Atherosclerosis Suppl 2005; 6(4): 3-11.

Thompson PD, Zimet R, Porbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. American Journal of Cardiology 2002; 90 (12): 1314-1319.

Tamai Y, Takami H, Nakahata R, et al. Comparison of the effects of acetylsalicylic acid, ticlopidine and ciloztazol on primary hemostasis using a quantitative bleeding time test apparatus. Pathophysiolofy of Haemostasis and Thrombosis 1999; 29 (5): 269-276.

Ahn CW, Lee HC, Park SW, et al. Decrease in carotid intima media thickness after 1 years of cilostazol treatment in patient with type-2 diabetes mellitus. Diabetes Research Clin Pract 2001; 52 (1): 45-53.




DOI: http://dx.doi.org/10.20527/jbk.v10i1.932

Article Metrics

Abstract view : 106 times
PDF - 0 times

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Jurnal Berkala Kedokteran

Indexed by :

          

 

 

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

joomla
visitors View My Stats